Avalyn Pharma Inc (AVLN) FinancialsAVLNAvalyn Pharma Inc

In the context of the broader market, AVLN competes directly with industry leaders such as HROW and IMTX. With a market capitalization of $1.26B, it holds a leading position in the sector. When comparing efficiency, AVLN's gross margin of N/A stands against HROW's 71.27% and IMTX's 100.00%. Such benchmarking helps identify whether Avalyn Pharma Inc is trading at a premium or discount relative to its financial performance.

Avalyn Pharma has reported a net income loss of -28.9 million in Q2 2026, with an EPS of -0.98. Despite these losses, the company has a strong current ratio of 33.12, indicating good short-term financial health.